High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
635.06M
-0.85%
-0.212
-13.3%
632.60M
+0.51%
-0.300
+37.11%
635.34M
+0.54%
-0.225
+52.75%
Estimates Revision
The market is revising Upward the revenue expectations for Teladoc Health, Inc. (TDOC) for FY2025, with the revenue forecasts being adjusted by 0.07% over the past three months. During the same period, the stock price has changed by -0.51%.
Revenue Estimates for FY2025
Revise Upward
+0.07%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-17.51%
In Past 3 Month
Stock Price
Go Down
-0.51%
In Past 3 Month
13 Analyst Rating
Wall Street analysts forecast TDOC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TDOC is 9.41 USD with a low forecast of 8.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
11 Hold
0 Sell
Hold
Current: 7.780
Low
8.00
Averages
9.41
High
12.00
Current: 7.780
Low
8.00
Averages
9.41
High
12.00
BofA
Neutral
downgrade
$9 -> $8
2025-11-25
Reason
BofA
Price Target
$9 -> $8
2025-11-25
downgrade
Neutral
Reason
BofA lowered the firm's price target on Teladoc to $8 from $9 and keeps a Neutral rating on the shares. October BetterHelp MAUs are tracking above the Q3 average, but the firm remains cautious on near-term trends given it is early in Q4 and management's commentary that weaker consumer sentiment and macro uncertainties were consistent through Q3, the analyst tells investors.
BMO Capital
Sean Dodge
Market Perform
initiated
$8
2025-11-12
Reason
BMO Capital
Sean Dodge
Price Target
$8
2025-11-12
initiated
Market Perform
Reason
BMO Capital analyst Sean Dodge initiated coverage of Teladoc with a Market Perform rating and $8 price target. Teladoc remains the leading telehealth and virtual mental health provider, though growth has slowed since the pandemic, the analyst tells investors in a research note. Management's efforts to revive revenue show early promise, and greater adoption of BetterHelp through insurance, stabilization of U.S. cash-pay users, and sustained international momentum could strengthen the outlook, the firm says.
BofA
Neutral
maintain
$9
2025-10-24
Reason
BofA
Price Target
$9
2025-10-24
maintain
Neutral
Reason
BofA raised the firm's price target on Teladoc to $9 from $8.50 and keeps a Neutral rating on the shares after the company announced a CFO transition, reaffirmed its 2025 revenue and adjusted EBITDA outlook and provided preliminary Q3 results. The firm continues to view Teladoc as a differentiated asset given its broad scale and optionality from recent acquisitions, but remains cautious on the near-term outlook, the analyst tells investors.
Citi
Daniel Grosslight
Neutral
maintain
2025-10-21
Reason
Citi
Daniel Grosslight
Price Target
2025-10-21
maintain
Neutral
Reason
Citi analyst Daniel Grosslight raised the firm's price target on Teladoc to $10.50 from $9.50 and keeps a Neutral rating on the shares as part of a Q3 earnings preview. Citi is "encouraged" by third-party data regarding Teladoc's trends and believes BetterHelp's results will surprise to the upside.
Cantor Fitzgerald
Sarah James
Overweight
downgrade
$12 -> $10
2025-07-30
Reason
Cantor Fitzgerald
Sarah James
Price Target
$12 -> $10
2025-07-30
downgrade
Overweight
Reason
Cantor Fitzgerald analyst Sarah James lowered the firm's price target on Teladoc to $10 from $12 and keeps an Overweight rating on the shares. Teladoc's long-term growth in BetterHelp is heavily levered towards insurance coverage, but there are more pathways to sustainable growth in Integrated Care, the analyst tells investors in a research note. The firm believes more proof is needed on a return to revenue growth in BetterHelp before the multiple lifts.
Mizuho
Steven Valiquette
Neutral
initiated
$10
2025-07-25
Reason
Mizuho
Steven Valiquette
Price Target
$10
2025-07-25
initiated
Neutral
Reason
Mizuho analyst Steven Valiquette initiated coverage of Teladoc with a Neutral rating and $10 price target. The firm is encouraged by Teladoc's growth in its Integrated Care segment but is concerned about the potential pace of BetterHelp attrition over the near term. The company's customer acquisition costs remain elevated, and consumer sentiment remains well below historical averages in 2025, the analyst tells investors in a research note.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Teladoc Health Inc (TDOC.N) is -8.48, compared to its 5-year average forward P/E of -32.95. For a more detailed relative valuation and DCF analysis to assess Teladoc Health Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-32.95
Current PE
-8.48
Overvalued PE
8.59
Undervalued PE
-74.49
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
31.11
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
67.34
Undervalued EV/EBITDA
-5.12
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
3.70
Current PS
0.00
Overvalued PS
8.44
Undervalued PS
-1.05
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
TDOC News & Events
Events Timeline
(ET)
2025-10-29
16:30:47
Teladoc projects FY25 EPS between $1.25 and $1.10, compared to consensus estimate of $1.16.
2025-10-29
16:28:01
Teladoc Projects Q4 EPS Between (25c) and (10c), Below Consensus Estimate of (26c)
2025-10-29
16:26:27
Teladoc Announces Q3 Earnings Per Share of 28 Cents, Exceeding Consensus Estimate of 23 Cents
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/940a3cff0f642b151a2c8e7a632dc3b261353b585a06b5a5d009b22fd8986bc2.jpg)
Preview
4.0
11-26NASDAQ.COMB of A Securities Upholds Neutral Rating on Teladoc Health (TDOC)
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/prnewswire.png)
Preview
7.5
11-18PRnewswireTytoCare Integrates With Teladoc Health to Augment Virtual Primary and Urgent Care
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/e89cb7609ff0e21cafff0773d1c4af39060d164a5c47332de600f3c2b8f7f81a.jpg)
Preview
9.5
11-12NASDAQ.COMTeladoc Health Reports Increased Q3 Loss Compared to Last Year Due to Struggles in BetterHelp Division
Sign Up For More News
People Also Watch
FAQ
What is Teladoc Health Inc (TDOC) stock price today?
What is Teladoc Health Inc (TDOC)'s business?
What is the price predicton of TDOC Stock?
What is Teladoc Health Inc (TDOC)'s revenue for the last quarter?
What is Teladoc Health Inc (TDOC)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Teladoc Health Inc (TDOC)'s fundamentals?
How many employees does Teladoc Health Inc (TDOC). have?